SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 195.83-0.7%Dec 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Machaon who wrote (24434)8/13/1998 11:05:00 AM
From: Mudcat  Read Replies (2) of 32384
 
<"we" as shareholders just bought around $220 million in drug development and science, and a revenue producing drug, for about $75 million>

The above is just more of the Barry convoluted logic. I look at it this way, SRGN has 28.1M shares outstanding, in April they were about 40 cents a share. This equates to a market cap of $11.2M. So I see "we" shareholders paying $75M for a company that was close to bankruptcy with a market cap of approximately $11M. Funny how we see things so different Barry.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News